发明公开
EP2376455A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
有权
吡啶和CARBOXYPYRIDINVERBINDUNGEN ALS磷酸二酯酶抑制剂10
- 专利标题： AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
- 专利标题（中）： 吡啶和CARBOXYPYRIDINVERBINDUNGEN ALS磷酸二酯酶抑制剂10
-
申请号： EP09793422.8申请日： 2009-12-16
-
公开(公告)号： EP2376455A1公开(公告)日： 2011-10-19
- 发明人: ALLEN, Jennifer R. , CHEN, Ning , FALSEY, James R. , FROHN, Michael , HARRINGTON, Paul , HU, Essa , KALLER, Matthew R. , KUNZ, Roxanne , MERCEDE, Stephanie J. , NGUYEN, Thomas T. , PICKRELL, Alexander J. , REICHELT, Andreas , RUMFELT, Shannon , RZASA, Robert M. , SHAM, Kelvin , SIEGMUND, Aaron C. , TEGLEY, Christopher M. , YAO, Guomin
- 申请人： Amgen Inc.
- 申请人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 专利权人： Amgen Inc.
- 当前专利权人： Amgen Inc.
- 当前专利权人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 代理机构： Grünecker, Kinkeldey, Stockmair & Schwanhäusser
- 优先权： US138443P 20081217; US138434P 20081217
- 国际公布： WO2010077992 20100708
- 主分类号： C07D213/74
- IPC分类号： C07D213/74 ; C07D213/84 ; C07D401/12 ; C07D401/14 ; C07D407/14 ; C07D409/14 ; C07D413/14 ; A61K31/444 ; A61P25/18
摘要：
Pyridine and pyrimidine compounds: (I); or a pharmaceutically acceptable salt thereof, wherein m, n, R
1 , R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , X
1 , X
2 , X
3 , X
4 , X
5 , X
6 , X
7 , X
8 , and Y are as defined in the specification; (II); or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , R
8 , R
9 , X
1 , X
2 , and ring A are as defined in the specification; and (III); or a pharmaceutically acceptable salt thereof, wherein m, n, y, R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , R
9 , X
1 , X
2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
1 , R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , X
1 , X
2 , X
3 , X
4 , X
5 , X
6 , X
7 , X
8 , and Y are as defined in the specification; (II); or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , R
8 , R
9 , X
1 , X
2 , and ring A are as defined in the specification; and (III); or a pharmaceutically acceptable salt thereof, wherein m, n, y, R
2 , R
3 , R
4 , R
5 , R
6 , R
7 , R
9 , X
1 , X
2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
公开/授权文献
信息查询
IPC分类:
